| Kerri-Ann Millar |
Kerri-Ann Millar currently works at Cue Biopharma, Inc., as Chief Financial Officer from 2020. Ms. Millar also formerly worked at Flexion Therapeutics, Inc., as Controller from 2014 to 2017. Ms. Millar received her undergraduate degree in 1992 from Boston University. |
| Frank M. Morich |
Dr. Frank M. Morich is an Independent Director at Perspective Therapeutics, Inc., an Executive Chairman at Aphaia Pharma AG and a Chairman at Cue Biopharma, Inc. He is on the Board of Directors at Perspective Therapeutics, Inc. and Viewpoint Molecular Targeting, Inc. Dr. Morich was previously employed as a Deputy Chairman-Supervisory Board by MorphoSys AG, a Director & Chief Commercial Officer by Takeda Pharmaceutical Co., Ltd., an Executive Vice President by Takeda Pharmaceuticals International, Inc., a Chief Commercial Officer by Takeda Pharmaceuticals International AG, a Chief Executive Officer by NOXXON Pharma AG, a Chief Executive Officer & Director by Innogenetics NV, a Member-Supervisory Board by Innate Pharma SA, a Chairman by Bayer HealthCare AG, a Director-Clinical Research by Miles, Inc., a Chairman-Executive Board & Chie Executive Officer by AM-Pharma BV, a Member-Supervisory Board by Neuro3D SA, and a President & Chief Executive Officer by Takeda A/S. He also served on the board at IsoRay, Inc., Viewpoint (US), Bayer AG and Bayer Corp. He received his doctorate degree from Philipps University of Marburg. |
| Daniel G. Baker |
Daniel G. Baker currently works at Artiva Biotherapeutics, Inc., as Independent Director from 2025 and Cue Biopharma, Inc., as Chief Development Officer from 2024. Dr. Baker also formerly worked at Kira Biotech Pty Ltd., as Chief Executive Officer & Executive Director from 2019 to 2024 and Galapagos NV, as Independent Non-Executive Director from 2022 to 2024. Dr. Baker received his doctorate degree from the University of Pennsylvania and undergraduate degree from Gettysburg College. |
| Daniel R. Passeri |
Daniel R. Passeri currently works at Cue Biopharma, Inc., as CEO, CFO, CAO & Director from 2025. Mr. Passeri also formerly worked at Curis, Inc., as Vice Chairman from 2014 to 2016, Xequel Bio, Inc., as Vice Chairman, Boehringer Mannheim Pharmaceuticals Corp., as Director-Technology Management in 1997, Gene Logic, Inc., as SVP-Corporate Development & Strategic Planning from 1997 to 2000, and Genomic Medicine, Inc., as Head-Technology Management & Business Development from 2014 to 2015. Mr. Passeri received his graduate degree from Imperial College London and undergraduate degree from Northeastern University. |
| Matteo Levisetti |
Matteo Levisetti currently works at Cue Biopharma, Inc., as Chief Medical Officer from 2023. Dr. Levisetti also formerly worked at Mirati Therapeutics, Inc., as Executive Director-Clinical Development from 2016 to 2017, Roche Pharmaceuticals, Inc., as Global Head & VP-Translational Medicine, DNAtrix, Inc., as Chief Medical Officer from 2019 to 2021, Washington University School of Medicine, as Assistant Professor, and Dauntless Pharmaceuticals, Inc., as Chief Medical Officer from 2017 to 2018. Dr. Levisetti received his doctorate degree in 1996 from Pritzker School of Medicine. |
| Peter Alec Kiener |
Peter Alec Kiener was the founder of Zyngenia, Inc. (2009) as President, Chief Executive Officer & Director. Current jobs include Chairman at Resolve Therapeutics LLC, Director at AbCellera Boston, Inc., Independent Director at Cue Biopharma, Inc. (2020), Independent Non-Executive Director at LAVA Therapeutics NV (2023), Director at Wugen, Inc., Director at Itolerance, Inc., Venture Partner at Intermediate Capital Group Plc (Private Equity), and Venture Partner at Bridge Valley Ventures LLP. Former jobs include Chief Executive Officer at Cereius, Inc. (2019-2020), Director at GT Biopharma, Inc. (2018-2019), Director at Receptor BioLogix, Inc., Director at Adheron Therapeutics, Inc., Director at Virdante Pharmaceuticals, Inc., Director at Viral Logic Systems Technology Corp., Independent Director at Pieris Pharmaceuticals, Inc. (2018-2024), Head-Global Research & Development at Bristol Myers Squibb Co. (1983-2001), Executive Vice President-Research & Development at MedImmune LLC (2001-2009), Executive Vice President at AstraZeneca PLC (2009), Principal at the University of Oxford, Assistant Professor at the University of North Texas (1982-1983), Research Associate at the University of Massachusetts (1978-1982), Chief Science Officer at Ambrx, Inc. (2013-2014), and Chief Scientific Officer at Sucampo Pharmaceuticals LLC (2014-2018). Education includes a doctorate from the University of Oxford (1978) and an undergraduate degree from the University of Lancaster (1973). |
| Lucinda Warren |
Lucinda Warren currently works at International Schools Services, Inc., as Director, Association of Strategic Alliance Professionals, as Director, Vitaco Holdings Ltd., as Chief People & Culture Officer, and Cue Biopharma, Inc., as Chief Business Officer from 2024. Ms. Warren also formerly worked at Johnson & Johnson Innovation LLC, as Vice President-Business Development from 2014 to 2024. Ms. Warren received her undergraduate degree from the University of Alberta. |
| Frederick W. Driscoll |
Frederick W. Driscoll is currently serving as the Non-Executive Chairman at MEI Pharma, Inc. since 2024. He is also an Independent Director at Cellectar Biosciences, Inc. since 2017, an Independent Director at Cue Biopharma, Inc. since 2018, a Director at SmartPharm Therapeutics, Inc. since 2019, and a Director at NeoSoma, Inc. since 2023. Previously, Mr. Driscoll held the position of Chairman, President & Chief Executive Officer at Oncotelic Therapeutics, Inc. from 2000 to 2006. He was the President & Chief Executive Officer at Genelabs Technologies, Inc. from 2008 to 2009. He also served as the Lead Independent Director at NantKwest, Inc. Additionally, he held various director positions at Cynapsus Therapeutics, Inc., Abpro Corp., ImmunityBio, Inc., and Calliditas Therapeutics AB. Mr. Driscoll was the Chief Financial Officer, Treasurer & VP at Novavax, Inc. from 2012 to 2013, the Chief Financial Officer & Treasurer at ConforMIS, Inc. from 2019 to 2020, and the Chief Financial Officer at Flexion Therapeutics, Inc. from 2013 to 2017. He also served as the Vice President-Finance-Americas & Controller at Instrumentation Laboratory Co. from 1974 to 2006, the Chief Financial Officer at Astraris, Inc. from 2006 to 2007, and the Senior Vice President-Finance & Operations at Collagenesis Corp. from 1996 to 2000. Mr. Driscoll holds an undergraduate degree from Bentley University, which he obtained in 1972. |
| Patrick Verheyen |
Patrick Verheyen currently works at The Bioindustry Association, as Director and Cue Biopharma, Inc., as Independent Director from 2023. Mr. Verheyen also formerly worked at Cougar Biotechnology, Inc., as Director in 2009. Mr. Verheyen received his graduate degree from Katholieke Universiteit Leuven. |
| Pamela D. Garzone |
Pamela D. Garzone currently works at Cue Biopharma, Inc., as Independent Director from 2023 and Anixa Biosciences, Inc., as Chief Development Officer from 2021. Dr. Garzone also formerly worked at the University of Pittsburgh, as Assistant Professor. Dr. Garzone received her graduate degree and doctorate degree from the University of Pittsburgh and undergraduate degree from Purdue University. |
